1-3 of 3
Rebekah Conlon
Close
Sort by
Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Kim Linton, Wojciech Jurczak, Pieternella Lugtenburg, Emmanuel Gyan, Anna Maria Sureda Balari, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raul Cordoba, David Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Umberto Vitolo, Tara Cochrane, Sirpa Leppa, Martine E.D. Chamuleau, Rebekah Conlon, Elena Favaro, Diana Gernhardt, Isil Altintas, Yan Liu, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1655.
https://doi.org/10.1182/blood-2023-179887
Published: 2023
Journal Articles

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Lorenzo Falchi, Franck Morschhauser, John G. Gribben, Huiqiang Huang, Minh Dinh, Rebekah Conlon, Xiaorong Chen, Brian Elliot, John F. Seymour
Journal: Blood
Blood (2022) 140 (Supplement 1): 9338–9339.
https://doi.org/10.1182/blood-2022-157584
Published: 2022
Journal Articles

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Nicholas Allen Forward, MDMSc,FRCPC, Pierre Laneuville, MD FRCPC, Joy Mangel, MD FRCPC, Douglas A. Stewart, MD FRCPC, Irina Amitai, MD, Gail Klein, MSc, Nancy Pennell, BSc, Iran Rashedi, MD MSc, Kim Roos, BA, BSc, Yogesh Bramhecha, Rebekah Conlon, RN
Journal: Blood
Blood (2020) 136 (Supplement 1): 16.
https://doi.org/10.1182/blood-2020-136751
Published: 2020